Know More, Sooner

Identify High Risk Patients
Test for presence of MRD after definitive therapy to assess prognosis1-2
93%-100%
sensitivity for predicting recurrence1-2

Detect Recurrence Earlier
Detect recurrence before radiographic imaging1-2
4-5 months
mean lead time over radiographic recurrence1-2

Monitor Treatment Response
Track changes in ctDNA levels to evaluate treatment response3
100% OS*
for patients who cleared ctDNA during IO (immunotherapy)3
Evaluate Response to ICI Treatment
ICIs (immune checkpoint inhibitors) are FDA-approved with guideline recommendations across all treatment settings in lung cancer (neoadjuvant, adjuvant, locally advanced, metastatic).4
The Signatera™ Residual Disease Test was evaluated in the INSPIRE trial, a randomized, prospective study in patients with advanced or metastatic solid malignancies receiving an anti-PD-1 treatment:3
-
An increase in ctDNA levels from baseline to week 6 strongly predicted disease progression and nonresponse to treatment.3
-
Overall survival was 100% in patients who experienced ctDNA clearance for at least one on-treatment time point.3

Inform Your Lung Cancer Treatment Approach With Signatera™
Monitoring circulating tumor DNA (ctDNA) with Signatera™ across the treatment journey can answer important clinical questions and inform treatment decisions.

Discover the Data in Lung Cancer
-
Adjuvant / Surveillance
- 93% sensitivity for predicting recurrence
- 4 month mean lead time for detecting recurrence vs. radiographic imaging1
-
Unresectable Disease / Surveillance
-
Immunotherapy Response Monitoring

Do More With Less Tissue
One tumor sample – two tests
Reassure Your Patients Living With Lung Cancer
After JoAnn was diagnosed with lung cancer, Signatera™ detected a rise in her ctDNA levels, alerting her oncologist to a progression that was not scannable.
Watch JoAnn’s story to learn how she and her oncologist added Signatera™ testing to their toolbelt to help closely monitor her cancer.
“I want to know. The more you know, the better off you are.” – JoAnn, living with lung cancer
Lung Cancer Resources

Medicare Coverage
Signatera™ is covered by Medicare for immunotherapy treatment response monitoring across all solid tumor types and stages of cancer.

IO Monitoring Brochure
Learn how Signatera™ can assess immunotherapy response as early as 6 weeks into treatment for patients with solid tumors.3

Patient Case Study
Read how Signatera™ detected a rise in ctDNA levels during immunotherapy, informing the decision to pivot to a combination therapy approach.
Ready to try Signatera™ for your lung cancer patients?
References
1Abbosh C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. https://doi.org/10.1038/nature22364
2Lebow ES, et al. Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy. Journal of Clinical Oncology 2022 40:16_suppl, 8540-8540. https://doi.org/10.1200/JCO.2022.40.16_suppl.8540
3Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873-881. https://doi.org/10.1038/s43018-020-0096-5
4NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2022